Species distribution and antifungal susceptibility patterns of Candida spp. bloodstream isolates from a Brazilian tertiary care hospital

Mycopathologia

Volumn 163, Issue 3, 2007, Pages 145-151

  Passos, Xisto Sena ^a   Costa, Carolina Rodrigues ^b   Araújo, Crystiane Rodrigues ^b   Nascimento, Elisa Sales ^b   E Souza, Lúcia Kioko Hasimoto ^b   De Fátima Lisboa Fernandes, Orionalda ^b   Sales, Werther Souza ^b   Do Rosário Rodrigues Silva, Maria ^b,c  

^a PAULISTA UNIVERSITY   (Brazil)

^b FEDERAL UNIVERSITY OF GOIÁS   (Brazil)

^c NONE   (Brazil)

Author keywords

Antifungal; Candidemia; Intensive care unit; Risk factors; Susceptibility testing

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; FLUCONAZOLE; ITRACONAZOLE; PYRIMIDINE DERIVATIVE; TRIAZOLE DERIVATIVE; VORICONAZOLE;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; BRAZIL; CANDIDA; CANDIDIASIS; CLASSIFICATION; DRUG EFFECT; FEMALE; HOSPITAL; HUMAN; INTENSIVE CARE UNIT; ISOLATION AND PURIFICATION; MALE; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; MIDDLE AGED; RISK FACTOR;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AMPHOTERICIN B; ANTIFUNGAL AGENTS; BRAZIL; CANDIDA; CANDIDIASIS; DRUG RESISTANCE, FUNGAL; FEMALE; FLUCONAZOLE; HOSPITALS; HUMANS; INTENSIVE CARE UNITS; ITRACONAZOLE; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PYRIMIDINES; RISK FACTORS; TRIAZOLES;

CANDIDA;

EID: 33947530627     PISSN: 0301486X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11046-007-0094-5     Document Type: Article

References (32)

1. Edmond MB, Wallace SE, McClish DK, Pfaller MA, Jones RN, Wenzel RP. Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin Infect Dis 1999; 29: 239-244.
2. Peres-Bota D, Rodriguez-Villalobos H, Dimopoulos G, Melot C, Vicent JL. Potential risk factors for infection with Candida spp. in critically ill patients. Clin Microbiol Infect Dis 2004; 10: 550-555.
3. Aquino VR, Lunardi LW, Goldani LZ, Barth AL. Prevalence, susceptibility profile for fluconazole and risk factors for candidemia in a tertiary care hospital in Southern Brazil. Braz J Infect Dis 2005; 9: 411-418.
4. Asai K, Tsuchimori N, Okonogi K, Perfect JR, Gotoh O, Yoshida Y. Formation of azole-resistant Candida albicans by mutation of sterol 14α-demethylase P450. Antimicrob Agents Chemother 1999; 43: 1163-1169.
5. Pfaller MA, Diekema DJ, Jones RN, Messer SA, Hollis RJ and the SENTRY participants group. Trends in Antifungal susceptibility of Candida spp. isolated from pediatric and adult patients with bloodstream infections: SENTRY Antimicrobial Surveillance Program, 1997 to 2000. J Clin Microbiol 2002; 40: 852-856.
6. Samra Z, Yardeni M, Peled N, Bishara J. Species distribution and antifungal susceptibility of Candida bloodstream isolates in a tertiary medical center in Israel. Eur J Clin Microbiol Infect Dis 2005; 24: 592-595.
7. Colombo AL, Nakagawa Z, Valdetaro F, Branchini MLM, Kussan EJU, Nucci M. Susceptibility profile of 200 bloodstream isolates of Candida spp. collected from brazilian tertiary care hospitals. Med Mycol 2003; 41: 235-239.
8. Antunes AGV, Pasqualotto AC, Diaz MC, d́Azevedo PA, Severo LC. Candidemia in a Brazilian tertiary care hospital: species distribution and antifungal susceptibility patterns. Rev Inst Med Trop São Paulo 2004; 46: 239-241.
9. Medrano DJA, Brilhante RSN, Cordeiro RA, Rocha MFG, Rabenhorst SHB, Sidrim JJ. Candidemia in a Brazilian hospital: the importance of Candida parapsilosis. Rev Inst Med Trop 2006; 48: 17-20.
10. Matsumoto FE, Gandra RF, Ruiz LS, Auler ME, Marques SAV, Pires MFC, Gambale W, Paula CR. Yeasts isolated from blood and catheter in children from a public hospital of São Paulo, Brazil. Mycopathologia 2001; 154: 63-69.
11. Ruiz LS, Sugizaki MF, Montelli AC, Matsumoto FE, Pires MFC, Da Silva BMC, Silva EH, Gandra RF, Silva EG, Auler ME, Paula CR. Fungemia by yeasts in Brazil: occurrence and phenotypic study of strains isolated at the public hospital, Botucatu, São Paulo. J Mycolog Med 2005; 15: 13-21.
12. Colombo AL, Nucci M, Park BJ, Nouér SA, Arthington-Skaggs B, da Matta DA, Warnock D, Morgan J. Epidemiology of candidemia in Brazil: a nationwide sentinel surveillance of candidemia in eleven medical centers. J. Clin Microbiol 2006; 44: 2816-2823.
13. Kurtzman CP, Fell JW. The yeasts, a taxonomic study (4th ed.). New York: Elsevier, 1998 891-947.
14. National Committee for Clinical Laboratory Standards.. Method for broth dilution antifungal susceptibility testing of yeasts: approved standard M27-A2. USA: NCCLS Villanova, PA, 2002.
15. Nguyen MH, Clancy CJ, Yu VL, Yu YC, Morris AJ, Snydman DR, Sutton DA, Rinaldi MG. Do in vitro susceptibility data predict the microbiological response to Amphotericin B? Results of a prospective study of patients with Candida fungemia. J Infect Dis 1998; 177: 425-430.
16. Pfaller MA, Diekema DJ, Jones RN, Sader HS, Fluit AC, Hollis RJ. International surveillance of bloodstream infections due to Candida species, frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program. J Clin Microbiol 2001; 39: 3254-3259.
17. Giusano G, Mangiaterra M, Saito VG, Rojas F, Gómez V, Diaz MC. Etiology of fungaemia and catheter colonisation in Argentinean paediatric patients. Mycoses 2006; 49: 49-54.
18. Luzzati R, Allegranzi B, Antozzi L, Masala L, Pegoraro E, Azzini A, Concia E. Secular trends in nosocomial candidaemia in non-neutropenic patients in na Italian tertiary hospital. Clin Microbial Infect 2005; 11: 908-913.
19. Trick WE, Fridklin SK, Edwards JR, Hajjeh RA, Gaynes RP. Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999. Clin Infect Dis 2002; 35: 627-630.
20. Colombo AL, Nucci M, Salomão R, Branchini MLM, Richtmann R, Derossi A, Wey SB. High rate of non-albicans candidemia in Brazilian tertiary care hospitals. Diagn Microbiol Infect Dis 1999; 34: 281-286.
21. Hajjeh RA, Sofair AN, Harrison LH, Lyon GM, Mirza AS, Phelan M, Morgan J, Lee-Yang W, Ciblak AM, Benjamin LE, Sanza LT, Huie S, Yeo SF, Brandt ME, Warnock DW. Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program. J Clin Microbiol 2004; 42: 1519-1527.
22. Godoy P, Tirabochi IN, Severo LC, Bustamante B, Calvo B, Almeida LP, Matta DA, Colombo AL. Species distribution and antifungal susceptibility profile of Candida spp. bloodstream isolates from Latin American Hospitals. Mem Inst Oswaldo Cruz 2003; 98: 401-405.
23. Nenoff P, Oswald U, Haustein F. In vitro susceptibility of yeasts for fluconazole and itraconazole. Evaluation of a microdilution test. Mycoses 1999; 42: 629-639.
24. Wingard JR. Importance of Candida species other than C. albicans as pathogens in oncology patients. Clin Infect Dis 1995; 20: 115-125.
25. Paula CR, Krebs VLJ, Auler ME, Ruiz LS, Matsumoto FE, Silva EH, Diniz EMA, Vaz FAC. Nosocomial infection in newborns by Pichia anomala in a Brazilian intensive care unit. Med Mycol 2006; 44: 479-484.
26. Pemán J, Cantón E, Gobernado M. Epidemiology and antifungal susceptibility of Candida species isolated from blood: results of a 2-year multicenter study in Spain. Eur J Clin Microbiol Infect Dis 2005; 24: 23-30.
27. Colombo AL, Perfect J, Dinubile M, Bartizal K, Motyl M, Hicks P, Lupinacci R, Sable C, Kartsonis N. Global distribution and outcomes for Candida species causing invasive candidiasis: results from an international randomized double-blind study of caspofungin versus amphotericin B for the treatment of invasive candidiasis. Eur J clin Microbiol Infect Dis 2003; 22: 470-474.
28. Pfaller MA, Diekema DJ, Mendez M, Kibbler C, Erzsebet P, Chang SC, Gibbs DL, Newell VA and the Global antifungal surveillance group. Candida guilliermondii, an opportunistic fungal pathogen with decreased susceptibility to fluconazole: geographic and temporal trends from the ARTEMIS DISK Antifungal surveillance program. J Clin Microbiol 2006; 44: 3551-3556.
29. Dóczi I, Dósa E, Hajdú E, Nagy E. Aetiology and antifungal susceptibility of yeast bloodstream infections in a Hungrian university hospital between 1996 and 2000. J Med Microbiol 2002; 51: 677-681.
30. Takakura S, Fujihara N, Saito T, Kudo T, Iinuma Y, Ichiyama S. National surveillance of species distribution in blood isolates of Candida species in Japan and their susceptibility to six antifungal agents including voriconazole and micafungin. J Antimicrobiol Chemother 2004; 53: 283-289.
31. Chrisssanthou E. Trends in antifungal susceptibility among Swedish Candida species bloodstream isolates from 1994 to 1998: comparion of the E-test and the sensititre yeast on colorimetric antifungal panel with the NCCLS M27-A reference method. J Clin Microbiol 2001; 39: 4181-4183.
32. Cuenca-Estrella M, Rondero L, García-Effrón G, Rodriguez-Tudela JL. Antifungal susceptibilities of Candida spp. isolated from blood in Spain and Argentina, 1996-1999. J Antimicrobiol Chemother 2002; 49: 981-987.